Opportunistic Infections Citation List:
April 29, 2009 - May 12, 2009
Opportunistic Fungi (Cryptococcus, Aspergillus, Candida, Histoplasma)
1. Bulky 1,4-benzoxazine derivatives with antifungal activity.
Fringuelli R, Giacchè N, Milanese L, Cenci E, Macchiarulo A, Vecchiarelli A, Costantino G, Schiaffella F.
Bioorg Med Chem. 2009 May 3. [Epub ahead of print]
PMID: 19433362 [PubMed - as supplied by publisher]
TB (Tuberculosis, Mycobacterium, Avium, Drug Resistant, MAC, MDR)
2. GEMFIBROZIL (LOPIDTM) INHIBITS LEGIONELLA PNEUMOPHILA AND MYCOBACTERIUM TUBERCULOSIS ENOYL-COA REDUCTASES AND BLOCKS INTRACELLULAR GROWTH OF THESE BACTERIA IN MACROPHAGES.
Reich-Slotky R, Kabbash CA, Della-Latta P, Blanchard JS, Feinmark SJ, Freeman S, Kaplan G, Shuman HA, Silverstein SC.
J Bacteriol. 2009 May 8. [Epub ahead of print]
PMID: 19429621 [PubMed - as supplied by publisher]
3. Synthesis and in vitro anti Mycobacterium tuberculosis activity of a series of phthalimide derivatives.
Santos JL, Yamasaki PR, Chin CM, Takashi CH, Pavan FR, Leite CQ.
Bioorg Med Chem. 2009 May 3. [Epub ahead of print]
PMID: 19427791 [PubMed - as supplied by publisher]
4. Synthetic EthR inhibitors boost antituberculous activity of ethionamide.
Willand N, Dirié B, Carette X, Bifani P, Singhal A, Desroses M, Leroux F, Willery E, Mathys V, Déprez-Poulain R, Delcroix G, Frénois F, Aumercier M, Locht C, Villeret V, Déprez B, Baulard AR.
Nat Med. 2009 May;15(5):537-44. Epub 2009 May 3.
PMID: 19412174 [PubMed - in process]
5. Peptide conjugates of therapeutically used antitubercular isoniazid-design, synthesis and antimycobacterial effect.
Horváti K, Mezo G, Szabó N, Hudecz F, Bosze S.
J Pept Sci. 2009 May;15(5):385-91.
PMID: 19319854 [PubMed - in process]
6. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis.
Makarov V, Manina G, Mikusova K, Möllmann U, Ryabova O, Saint-Joanis B, Dhar N, Pasca MR, Buroni S, Lucarelli AP, Milano A, De Rossi E, Belanova M, Bobovska A, Dianiskova P, Kordulakova J, Sala C, Fullam E, Schneider P, McKinney JD, Brodin P, Christophe T, Waddell S, Butcher P, Albrethsen J, Rosenkrands I, Brosch R, Nandi V, Bharath S, Gaonkar S, Shandil RK, Balasubramanian V, Balganesh T, Tyagi S, Grosset J, Riccardi G, Cole ST.
Science. 2009 May 8;324(5928):801-4. Epub 2009 Mar 19.
PMID: 19299584 [PubMed - in process]
7. Organotin meclofenamic complexes: Synthesis, crystal structures and antiproliferative activity of the first complexes of meclofenamic acid - novel anti-tuberculosis agents.
Kovala-Demertzi D, Dokorou V, Primikiri A, Vargas R, Silvestru C, Russo U, Demertzis MA.
J Inorg Biochem. 2009 May;103(5):738-44. Epub 2009 Jan 27.
PMID: 19237201 [PubMed - in process]
8. A macrolactone from benzo[a]phenazine with potent activity against Mycobacterium tuberculosis.
Silva RS, Pinto Mdo C, Goulart MO, de Souza Filho JD, Neves I Jr, Lourenço MC, Pinto AV.
Eur J Med Chem. 2009 May;44(5):2334-7. Epub 2008 Jun 26.
PMID: 18662840 [PubMed - in process]
Citations from the ISI Web of Knowledge Listings for O.I.
9. Horvati, K., et al.
Peptide conjugates of therapeutically used antitubercular isoniazid - design, synthesis and antimycobacterial effect
JOURNAL OF PEPTIDE SCIENCE 2009 (May) 15: 385 - 391
10. Klimesova, V., et al.
Preparation and in vitro evaluation of benzylsulfanyl benzoxazole derivatives as potential antituberculosis agents
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 2009 (May) 44: 2286 - 2293
11. Silva, RSF., et al.
A macrolactone from benzo[a]phenazine with potent activity against Mycobacterium tuberculosis
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 2009 (May) 44: 2334 - 2337